ClinicaliQ Trial Snapshot
- Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer — Active Not Recruiting • Phase III • Oncology • NCT03528694.
- Durvalumab added to standard BCG therapy improved outcomes compared to BCG alone in non-muscle-invasive bladder cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer Conditions: Non-muscle-invasive Bladder Cancer Interventions: Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG) Lead Sponsor: AstraZeneca Planned Enrollment: 1018 participants